Scarica l'app Stockscreener
4.90
0.41%
-0.02
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché FHTX Giù?
Forum
Previsione
Foghorn Therapeutics Inc Borsa (FHTX) Ultime notizie
Foghorn Therapeutics’ (FHTX) Outperform Rating Reiterated at Wedbush - Defense World
Foghorn Therapeutics (FHTX) FY 2025 Losses Reinforce Bearish Unprofitability Narrative - simplywall.st
Jefferies reiterates Foghorn Therapeutics stock rating on pipeline data - Investing.com Australia
Jefferies reiterates Foghorn Therapeutics stock rating on pipeline data By Investing.com - Investing.com Nigeria
Foghorn Therapeutics reports $158.9M cash position, extends runway - Investing.com Australia
Stifel reiterates Foghorn Therapeutics stock rating at buy By Investing.com - Investing.com Australia
Stifel reiterates Foghorn Therapeutics stock rating at buy - Investing.com
Foghorn Therapeutics: Pioneering Precision Oncology with Chromatin Regulatory System Targeting and Gene Traffic Control Platform - Minichart
Foghorn Advances FHD-909 Trial and Strengthens Financial Position - TipRanks
Foghorn Therapeutics Inc. (FHTX) Posts Fourth Quarter Loss, Surpasses Revenue Projections - Bitget
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Foghorn Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Foghorn Therapeutics 10-K: $30.9M revenue, $(1.18) EPS - TradingView
Foghorn Therapeutics (NASDAQ:FHTX) Issues Quarterly Earnings Results, Misses Expectations By $0.04 EPS - MarketBeat
Foghorn Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook - GlobeNewswire
Foghorn Therapeutics (NASDAQ: FHTX) narrows 2025 loss and extends cash runway into 2028 - Stock Titan
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Foghorn Therapeutics (NASDAQ:FHTX) Given Buy Rating at HC Wainwright - Defense World
HC Wainwright Reiterates Buy Rating for Foghorn Therapeutics (NASDAQ:FHTX) - MarketBeat
HC Wainwright Reiterates Buy Rating for Foghorn Therapeutics (FH - GuruFocus
Aug Volume: Is Foghorn Therapeutics Inc part of any major index2026 Action & Low Volatility Stock Recommendations - baoquankhu1.vn
Will Foghorn Therapeutics Inc. stock benefit from AI adoptionForecast Cut & Smart Investment Allocation Insights - Naître et grandir
Foghorn Therapeutics Inc expected to post a loss of 25 cents a shareEarnings Preview - TradingView
FHTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
TD Cowen Health Care Conference - marketscreener.com
Should you avoid Foghorn Therapeutics Inc. stock right nowJuly 2025 Volume & Short-Term Trading Alerts - mfd.ru
Foghorn Therapeutics (FHTX) Projected to Post Earnings on Thursday - Defense World
Foghorn Therapeutics (FHTX) grants CFO 400,000 stock options - Stock Titan
Foghorn Therapeutics (FHTX) CFO files Form 3 insider ownership - Stock Titan
Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences - Investing News Network
Foghorn Therapeutics names Ryan Maynard as chief financial officer By Investing.com - Investing.com India
FHTXFoghorn Therapeutics Inc. Latest Stock News & Market Updates - Stock Titan
Foghorn Therapeutics names Ryan Maynard as chief financial officer - Investing.com
Foghorn Therapeutics (FHTX) Appoints New CFO with Extensive Expe - GuruFocus
Foghorn Therapeutics Appoints Ryan Maynard CFO - marketscreener.com
Foghorn Therapeutics Names Veteran Executive as New CFO - TipRanks
Foghorn Therapeutics Inc. Appoints Ryan Maynard as Chief Financial Officer - Quiver Quantitative
Ryan Maynard joins Foghorn Therapeutics (NASDAQ: FHTX) as new CFO - Stock Titan
Foghorn Therapeutics Inc. Announces Executive Changes - marketscreener.com
Will Foghorn Therapeutics Inc. (FHTX) Report Negative Q4 Earnings? What You Should Know - MSN
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Qiagen (QGEN) and Foghorn Therapeutics (FHTX) - The Globe and Mail
Investment Review: Does Aris Mining Corporation have a competitive edgeQuarterly Portfolio Summary & Verified Entry Point Detection - baoquankhu1.vn
Jefferies Financial Group Begins Coverage on Foghorn Therapeutics (NASDAQ:FHTX) - Defense World
Jefferies Lowers Price Target for Foghorn Therapeutics (FHTX) to $12.00 | FHTX Stock News - GuruFocus
Jefferies initiates Foghorn Therapeutics stock with buy rating By Investing.com - Investing.com Nigeria
Jefferies initiates Foghorn Therapeutics stock with buy rating - Investing.com
Can Foghorn Therapeutics Inc. stock double in the next yearProduct Launch & High Accuracy Investment Signals - mfd.ru
Foghorn Therapeutics appoints interim CFO Jeff Sacher - MSN
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Average Rating of “Buy” from Brokerages - Defense World
Foghorn Therapeutics CEO Talks Lilly-Partnered SMARCA2 Phase 1 and New Degrader Targets at Conference - MarketBeat
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):